Pharmacological effects of lecanemab: therapy for alzheimer's disease.

Izzi Hanberg*

School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland

Received date: *May 15, 2023, Manuscript No. AJPTI-23-104784;* ***Editor assigned date:*** *May 17, 2023, Pre QC No. AJPTI-23-104784 (PQ);* ***Reviewed date:*** *June 01, 2023, QC No. AJPTI-23-104784;* ***Revised date:*** *June 08, 2023, Manuscript No. AJPTI-23-104784 (R);* ***Published date:*** *June 16, 2023.*

Accepted on 25th June, 2023

Description

Lecanemab is an investigational drug that has shown significant promise in the treatment of Alzheimer's disease. As a monoclonal antibody targeting amyloid beta plaques, Lecanemab aims to slow down disease progression and potentially improve cognitive function in affected individuals. Lecanemab selectively binds to soluble and insoluble forms of aggregated Aβ peptides, which are believed to play a crucial role in the development and progression of Alzheimer's disease. By binding to Aβ plaques, Lecanemab facilitates the clearance and removal of these toxic protein aggregates from the brain. This mechanism is thought to reduce the burden of Aβ plaques and potentially mitigate their detrimental effects on neuronal function and synaptic transmission. Multiple clinical trials have been conducted to evaluate the efficacy and safety of Lecanemab in individuals with Alzheimer's disease. The Phase 2 trial, which involved individuals with mild cognitive impairment or mild Alzheimer's dementia, demonstrated encouraging results. The study showed a significant reduction in the accumulation of Aβ plaques in the brain as measured by Positron Emission Tomography (PET) imaging. Additionally, patients receiving higher doses of Lecanemab exhibited a slower decline in cognitive function compared to those receiving a placebo.

Lecanemab has undergone several clinical trials to evaluate its safety and efficacy. The Phase 2 clinical study showed promising results, demonstrating a statistically significant reduction in the levels of Aβ plaques in the brains of treated patients compared to the placebo group. There were trends toward improvement in cognitive and functional outcomes, although these results did not reach statistical significance.

Building upon the positive findings from Phase 2, two Phase 3 clinical trials these are currently on going to further investigate the potential benefits of lecanemab. These studies focus on early Alzheimer's disease patients with evidence of amyloid pathology. The primary endpoint of both trials is the change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score from baseline to 78 weeks.

Building on the positive outcomes of the Phase 2 trial, Phase 3 studies are currently underway to further assess the drug's efficacy and safety. These studies aim to evaluate the impact of Lecanemab on cognitive decline, functional abilities, and overall disease progression. If successful, Lecanemab could potentially become a breakthrough therapy for Alzheimer's disease.

The safety profile of Lecanemab is an important consideration in its clinical development. Overall, Lecanemab has shown a favourable safety profile in the completed Phase 2 trials. However, as with any investigational drug, side effects and adverse events have been reported, including infusion site reactions, headache, and Amyloid-Related Imaging Abnormalities (ARIA). ARIA is a known class effect of anti-amyloid antibodies, characterized by transient fluid build-up and inflammation in the brain. Nevertheless, most cases of ARIA were asymptomatic or mild and resolved without permanent consequences.

Lecanemab holds significant promise as a potential therapy for Alzheimer's disease. Its mechanism of action, targeting Aβ plaques, offers a novel approach to slow disease progression and potentially improve cognitive function in affected individuals. While Phase 2 trials have shown promising results, on-going Phase 3 studies will provide further insights into the drug's efficacy and safety. With the urgent need for effective treatments for Alzheimer's disease, Lecanemab represents a hopeful development that could make a substantial difference in the lives of patients and their families. Continued research and clinical trials will help determine its long-term benefits and establish its role in the management of this debilitating condition.

*Correspondence to:

Izzi Hanberg,

School of Pharmaceutical Sciences,

University of Geneva,

Geneva,

Switzerland,

E-mail: hanbergizzi@gmail.com

Citation: *Hanberg I. Pharmacological Efects Of Lecanemab: Therapy For Alzheimer's Disease AJPTI 2023;11 (42):1.*